Literature DB >> 2894220

CSF concentrations of famotidine.

I Kagevi1, E Thorhallsson, L Wählby.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2894220      PMCID： PMC1386419          DOI： 10.1111/j.1365-2125.1987.tb03261.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  7 in total

1.  CSF concentrations of ranitidine.

Authors:  I Kagevi; L Wählby
Journal:  Lancet       Date:  1985-01-19       Impact factor: 79.321

2.  Analytical method for the quantification of famotidine, an H2-receptor blocker, in plasma and urine.

Authors:  W C Vincek; M L Constanzer; G A Hessey; W F Bayne
Journal:  J Chromatogr       Date:  1985-03-22

3.  Mental confusion associated with ranitidine.

Authors:  J D Hughes; W D Reed; C S Serjeant
Journal:  Med J Aust       Date:  1983-07-09       Impact factor: 7.738

4.  No detectable concentrations of oxmetidine but measurable concentrations of cimetidine in cerebrospinal fluid (CSF) during multiple dose treatment.

Authors:  K A Jönsson; S E Eriksson; I Kagevi; B Norlander; G Bodemar; A Walan
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

5.  H2 histaminic receptors in rat cerebral cortex. 2. Inhibition of [3H]histamine by H2 antagonists.

Authors:  G H Steinberg; M Kandel; S I Kandel; J W Wells
Journal:  Biochemistry       Date:  1985-10-22       Impact factor: 3.162

6.  Cimetidine, but not oxmetidine, penetrates into the cerebrospinal fluid after a single intravenous dose.

Authors:  K A Jönsson; S E Eriksson; I Kagevi; B Norlander; G Bodemar; A Walan
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

7.  Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.

Authors:  J J Schentag; F B Cerra; G Calleri; E DeGlopper; J Q Rose; H Bernhard
Journal:  Lancet       Date:  1979-01-27       Impact factor: 79.321
  7 in total
  10 in total

Review 1.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 3.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

4.  A comparison of the cholinergic activity of selected H2-antagonists and sulfoxide metabolites.

Authors:  J W Kosh; J W Sowell; J M Chapman
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

Review 5.  Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

6.  Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics.

Authors:  Heidrun Appl; Tobias Holzammer; Stefan Dove; Ekkehard Haen; Andrea Strasser; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-10-28       Impact factor: 3.000

7.  Famotidine activates the vagus nerve inflammatory reflex to attenuate cytokine storm.

Authors:  Huan Yang; Sam J George; Dane A Thompson; Harold A Silverman; Téa Tsaava; Aisling Tynan; Valentin A Pavlov; Eric H Chang; Ulf Andersson; Michael Brines; Sangeeta S Chavan; Kevin J Tracey
Journal:  Mol Med       Date:  2022-05-16       Impact factor: 6.376

8.  Famotidine as an adjunct treatment of resistant schizophrenia.

Authors:  L K Oyewumi; D Vollick; H Merskey; C Plumb
Journal:  J Psychiatry Neurosci       Date:  1994-03       Impact factor: 6.186

Review 9.  Clinical pharmacokinetics of famotidine.

Authors:  H Echizen; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

10.  Famotidine activates the vagus nerve inflammatory reflex to attenuate cytokine storm.

Authors:  Huan Yang; Sam J George; Dane Thompson; Harold A Silverman; Tea Tsaava; Aisling Tynan; Valentin A Pavlov; Eric Chang; Ulf Andersson; Michael Brines; Sangeeta S Chavan; Kevin J Tracey
Journal:  Res Sq       Date:  2022-04-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.